Chemokine mutants acting as chemokine antagonists
US7553483B2 · kind B2 · utility
1Cited by
2References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2002 |
| Grant date | Jun 30, 2009 |
| Priority date | — |
| Expiry date | Feb 22, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.